Both of Germany’s chambers of parliament have now passed the diagnosis related groups (DRGs) and hospital reform bill (the Krankenhausversorgungsverbesserungsgesetz – KHVVG), which will come into force in stages as of 1 January 2025. Provisions will continue to be introduced piecemeal until 2029.
Germany’s DRGs And Hospital Reform Cleared For January Launch
Dissenters In Bundesrat Not Able To Muster Enough Support To Delay Bill
Germany’s governing coalition may have folded, but embattled health minister Lauterbach has championed his hospital reform bill to the last. Now voted through in the upper house of parliament, the bill to reform diagnosis related groups and hospital care delivery will come into force on 1 January.
More from Medica
• By
The UK market has become tougher for smaller innovators, says Andy Mears, CEO of Deltex Medical, which plans to launch a new iteration of its minimally invasive ultrasound-based technology, the oesophageal Doppler monitor. He explained how market access challenges have steepened.
• By
When federal chancellor Olaf Scholz lost his parliamentary vote of confidence in mid-December, it officially opened up the way for the elections the German leader had already penciled in for 23 February. The medtech industry has not been slow to set out its demands of the incoming government.
• By
The implosion of the German coalition government left unfinished business for the medtech industry. The coalition to emerge from the 23 February general election must consult more with industry, Spectaris’ head of medtech Marcus Kuhlmann said at Medica 2024.
• By
Germany’s governing coalition may have folded, but embattled health minister Lauterbach has championed his hospital reform bill to the last. Now voted through in the upper house of parliament, the bill to reform diagnosis related groups and hospital care delivery will come into force on 1 January.
More from Policy & Regulation
The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.
• By
A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.
• By
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.